A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.
about
Driving chronicity in rheumatoid arthritis - perpetuating role of myeloid cells.Investigational therapies targeting the granulocyte macrophage colony-stimulating factor receptor-α in rheumatoid arthritis: focus on mavrilimumab.GM-CSF targeted immunomodulation affects host response to M. tuberculosis infection.
P2860
A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.
@en
A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.
@nl
type
label
A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.
@en
A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.
@nl
prefLabel
A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.
@en
A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.
@nl
P2093
P2860
P356
P1476
A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.
@en
P2093
Alex Godwood
David Close
Iain B McInnes
Jiri Vencovsky
Joel M Kremer
Marius Albulescu
Michael E Weinblatt
Patricia C Ryan
Pedro Miranda
Wendy I White
P2860
P356
10.1002/ART.40323
P577
2017-09-21T00:00:00Z